{
    "root": "2a79d440-2b83-c291-e063-6294a90a55c9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Isoflurane",
    "value": "20250325",
    "ingredients": [
        {
            "name": "ISOFLURANE",
            "code": "CYS9AKD70P"
        }
    ],
    "indications": "Isoflurane USP may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia.",
    "contraindications": "• Isoflurane USP should be administered only by persons trained in the administration of general anesthesia. Isoflurane USP should only be delivered using a vaporizer specifically designed and designated for use with isoflurane. ( 2 ) • The administration of general anesthesia must be individualized and titrated based on the patient’s age and clinical status. ( 2 )",
    "warningsAndPrecautions": "Isoflurane USP, is available in the following presentations:\n                  \n                     \n                        \n                           \n                              FILL\n                           \n                           \n                              CONTAINER\n                           \n                           \n                              NDC\n                           \n                        \n                        \n                           100 mL\n                           Amber-colored Bottle\n                           66794-017-10\n                        \n                        \n                           250 mL\n                           Amber-colored Bottle\n                           66794-017-25\n                        \n                     \n                  \n                  Replace the cap securely after each use.",
    "adverseReactions": "Isoflurane USP is contraindicated in patients:\n                  \n                  • in whom general anesthesia is contraindicated.\n                  \n                     \n• with known sensitivity to Isoflurane USP or to other halogenated agents \n  [see Warnings and Precautions (\n                     5.3\n                     )].\n                  \n                  \n                     \n• with known or suspected genetic susceptibility to malignant hyperthermia \n  [see Warnings and Precautions (\n                     5.1\n                     ), Clinical Pharmacology (\n                     12.5\n                     )].\n                     \n                     \n• with a history of confirmed hepatitis due to a halogenated inhalational anesthetic or a history of unexplained moderate to severe hepatic dysfunction (e.g., jaundice associated with fever and/or eosinophilia) after anesthesia with isoflurane or other halogenated inhalational anesthetics."
}